Dissimilar Trypanosoma cruzi genotype-specific serological profile assessed by Chagas-Flow ATE IgG1 upon benznidazole etiological treatment of chronic Chagas disease.

Autor: Alessio, Glaucia Diniz, Silvestrini, Carolina Malheiros Araújo, Elói-Santos, Silvana Maria, Gontijo, Eliane Dias, Sales Júnior, Policarpo Ademar, Vitelli-Avelar, Danielle Marchetti, Sathler-Avelar, Renato, Wendling, Ana Paula Barbosa, Teixeira-Carvalho, Andréa, de Lana, Marta, Martins-Filho, Olindo Assis
Předmět:
Zdroj: PLoS Neglected Tropical Diseases; 9/13/2024, Vol. 18 Issue 9, p1-17, 17p
Abstrakt: The present study aimed to verify the impact of etiological treatment on the genotype-specific serological diagnosis of chronic Chagas disease patients (CH), using the Chagas-Flow ATE IgG1 methodology. For this purpose, a total of 92 serum samples from CH, categorized as Not Treated (NT, n = 32) and Benznidazole-Treated (Bz-T, n = 60), were tested at Study Baseline and 5Years Follow-up. At Study Baseline, all patients have the diagnosis of Chagas disease confirmed by Chagas-Flow ATE IgG1, using the set of attributes ("antigen/serum dilution/cut-off"; "EVI/250/30%"). The genotype-specific serodiagnosis at Study Baseline demonstrated that 96% of patients (44/46) presented a serological profile compatible with TcII genotype infection. At 5Years Follow-up monitoring, NT and Bz-T presented no changes in anti-EVI IgG1 reactivity. However, significant differences were detected in the genotype-specific IgG1 reactivity for Bz-T. The most outstanding shift comprised the anti-amastigote TcVI/(AVI), anti-amastigote TcII/(AII) and anti-epimastigote TcVI/(EVI) reactivities. Regardless no changes in the genotype-specific serology of NT (TcI = 6%; TcII = 94%), distinct T. cruzi genotype-specific sero-classification was detected for Bz-T samples at 5Years Follow-up (TcII = 100%) as compared to Baseline (TcII = 97%; TcVI = 3%). The anti-trypomastigote TcI/(TI) was the attribute accountable for the change in genotype-specific sero-classification. In conclusion, our findings of dissimilar T. cruzi genotype-specific serology upon Bz-treatment re-emphasize the relevance of accomplishing the genotype-specific serodiagnosis during clinical pos-therapeutic management of chronic Chagas disease patients. Author summary: Chagas disease is still a serious public health problem worldwide. Currently, only two drugs are available for the treatment of patients infected by T. cruzi: Benzonidazole and Nifurtimox. The efficacy of these compounds may differ depending on the phase of the disease when the treatment is established and also impacted by the T. cruzi genotypes that cause the infection. Thus, differences in therapeutic efficacy can be observed between geographic areas due to the distinct distribution of "Discrete Typing Unitys" (DTUs) of T. cruzi. Besides all these matters related to the etiological treatment, additional concerns regarding the laboratorial methods available for post-therapeutic monitoring of Chagas disease represent a challenge during clinical management. Amongst the innovative serological approaches, proposed for diagnosis and post-therapeutic monitoring of Chagas disease, the Chagas-Flow ATE IgG1 has been presented as an outstanding methodology, applicable for universal and genotype-specific serology. In the present study, the Chagas-Flow ATE IgG1 methodology was used for post-therapeutic monitoring of chronic Chagas disease patients, aiming at identifying changes in T. cruzi genotype-specific serological profile upon Benznidazole etiological treatment. This approach is relevant to provide novel insights to support the relevance of accomplishing the genotype-specific serodiagnosis during clinical pos-therapeutic management of chronic Chagas disease patients. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje